[go: up one dir, main page]

MX2009004439A - Composicion de ibuprofeno. - Google Patents

Composicion de ibuprofeno.

Info

Publication number
MX2009004439A
MX2009004439A MX2009004439A MX2009004439A MX2009004439A MX 2009004439 A MX2009004439 A MX 2009004439A MX 2009004439 A MX2009004439 A MX 2009004439A MX 2009004439 A MX2009004439 A MX 2009004439A MX 2009004439 A MX2009004439 A MX 2009004439A
Authority
MX
Mexico
Prior art keywords
water
ibuprofen composition
soluble acid
ibuprofen
solubility
Prior art date
Application number
MX2009004439A
Other languages
English (en)
Inventor
Robert Shen
Original Assignee
Mcneil Ppc Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mcneil Ppc Inc filed Critical Mcneil Ppc Inc
Publication of MX2009004439A publication Critical patent/MX2009004439A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se refiere a una tableta de liberación inmediata capaz de ser masticada o desintegrada en la cavidad oral, que comprende una pluralidad de partículas en una matriz; las partículas contienen un ingrediente activo, tal como ibuprofeno, y un primer ácido soluble en agua que tiene una solubilidad mayor que aproximadamente 10 g/100 ml de agua a 20°C; y la matriz contiene un segundo ácido soluble en agua que tiene una solubilidad menor que aproximadamente 5 g/100 ml de agua a 20°C.
MX2009004439A 2006-10-25 2007-10-24 Composicion de ibuprofeno. MX2009004439A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85434906P 2006-10-25 2006-10-25
PCT/US2007/082348 WO2008052033A2 (en) 2006-10-25 2007-10-24 Ibuprofen composition

Publications (1)

Publication Number Publication Date
MX2009004439A true MX2009004439A (es) 2009-05-11

Family

ID=39223093

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009004439A MX2009004439A (es) 2006-10-25 2007-10-24 Composicion de ibuprofeno.

Country Status (8)

Country Link
US (1) US20080113021A1 (es)
EP (1) EP2094248A2 (es)
CN (1) CN101528205A (es)
AU (1) AU2007308986A1 (es)
BR (1) BRPI0718428A2 (es)
CA (1) CA2667207A1 (es)
MX (1) MX2009004439A (es)
WO (1) WO2008052033A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2493465B1 (en) 2009-10-26 2014-10-22 Sephoris Pharmaceuticals, LLC Treatment of sunburn using analgesics and antihistamines
US20130217774A1 (en) * 2010-10-24 2013-08-22 Vivekanandan Sundaramoorthy Novel process for preparing dexibuprofen ready to compress granules
CN102258490B (zh) * 2011-07-01 2012-10-03 中美天津史克制药有限公司 布洛芬咀嚼片
HRP20171889T1 (hr) 2011-07-07 2018-01-12 Janssen Sciences Ireland Uc Formulacije kombinacije darunavira
CN102488681B (zh) * 2011-12-21 2013-03-13 西南大学 布洛芬苯海拉明口腔崩解片及其制备方法
BR112015005876A2 (pt) 2012-09-18 2017-07-04 Mcneil Ppc Inc partículas derivadas de ácido propiônico com baixo ponto de fusão para uso em formas de dosagem oral
WO2014047005A1 (en) 2012-09-18 2014-03-27 Mcneil-Ppc, Inc. Sustained release oral dosage forms comprising low melting propionic acid derivative particles
US9636305B2 (en) * 2013-03-14 2017-05-02 Redhill Biopharma Ltd. Antiemetic extended release solid dosage forms
BR112016020877B1 (pt) 2014-03-11 2022-11-29 Redhill Biopharma Ltd Uso de ondansetron, uso de um núcleo compreendendo uma matriz polímera não iônica e comprimido
US20150290174A1 (en) * 2014-04-11 2015-10-15 Resuscitate MOE LLC Pharmaceutical formulations and method of using the same for alleviating symptoms of hangover, stomach flu or migraine
US10420756B2 (en) * 2015-03-26 2019-09-24 Sen-Jam Pharmaceutical Llc. Methods and compositions to inhibit symptoms associated with veisalgia
MX383987B (es) * 2015-12-28 2025-03-14 Ssp Co Ltd Japan Preparación farmacéutica compactada.
CN111035764B (zh) * 2018-10-14 2021-09-07 深圳市健元医药科技有限公司 一种治疗类风湿性关节炎的组合物及其制备方法
TWI849062B (zh) 2019-02-22 2024-07-21 英商康泰倫特英國斯文敦載迪斯有限公司 保存水性懸浮液中以無溶劑混合方法製備的功能性塗覆之活性醫藥成份微粒
AU2020224375A1 (en) * 2019-02-22 2021-10-14 Catalent U.K. Swindon Zydis Limited Minimizing aeration of suspensions during in-line mixing
JP7628497B2 (ja) * 2019-02-22 2025-02-10 キャタレント・ユーケー・スウィンドン・ザイディス・リミテッド イブプロフェンを含む薬学的組成物の凝集、通気の最小化、及びコーティングの保存
GB2597579B (en) 2019-02-22 2023-04-26 Catalent Uk Swindon Zydis Ltd Minimizing agglomeration of drug particle coating material during storage to stabilize disintegration times of pharmaceutical products
BR112023001716A2 (pt) 2020-07-31 2023-04-04 Catalent Uk Swindon Zydis Ltd Composições farmacêuticas compreendendo api revestido

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54127247A (en) * 1978-03-27 1979-10-03 Toshiba Corp Microprogram controller
US4543370A (en) * 1979-11-29 1985-09-24 Colorcon, Inc. Dry edible film coating composition, method and coating form
US4683256A (en) * 1980-11-06 1987-07-28 Colorcon, Inc. Dry edible film coating composition, method and coating form
US4643894A (en) * 1984-07-24 1987-02-17 Colorcon, Inc. Maltodextrin coating
US4828841A (en) * 1984-07-24 1989-05-09 Colorcon, Inc. Maltodextrin coating
DE3440288C2 (de) * 1984-11-05 1987-03-12 Gergely, Gerhard, Dr.-Ing., Wien Pharmazeutische Zubereitung mit einem Gehalt an Ibuprofen sowie Verfahren zu ihrer Herstellung
US4802924A (en) * 1986-06-19 1989-02-07 Colorcon, Inc. Coatings based on polydextrose for aqueous film coating of pharmaceutical food and confectionary products
US4800087A (en) * 1986-11-24 1989-01-24 Mehta Atul M Taste-masked pharmaceutical compositions
US4966771A (en) * 1987-02-20 1990-10-30 Mcneilab, Inc. Gelatin coated caplets and process for making same
US4820524A (en) * 1987-02-20 1989-04-11 Mcneilab, Inc. Gelatin coated caplets and process for making same
US4867983A (en) * 1987-02-20 1989-09-19 Mcneilab, Inc. Method for double dipping gelating coated caplets
US4906478A (en) * 1988-12-12 1990-03-06 Valentine Enterprises, Inc. Simethicone/calcium silicate composition
US5275822A (en) * 1989-10-19 1994-01-04 Valentine Enterprises, Inc. Defoaming composition
IT1246383B (it) * 1990-04-17 1994-11-18 Eurand Int Metodo per il mascheramento del sapore di farmaci
US5089270A (en) * 1990-05-15 1992-02-18 L. Perrigo Company Capsule-shaped tablet
US5213738A (en) * 1990-05-15 1993-05-25 L. Perrigo Company Method for making a capsule-shaped tablet
US5409709A (en) * 1991-11-29 1995-04-25 Lion Corporation Antipyretic analgesic preparation containing ibuprofen
WO1993014158A1 (en) * 1992-01-17 1993-07-22 Berwind Pharmaceutical Services, Inc. Film coatings and film coating compositions based on cellulosic polymers and lactose
US5466865A (en) * 1993-07-02 1995-11-14 Ibah, Inc. Neomorphic ibuprofen and methods of using same
US6103260A (en) * 1997-07-17 2000-08-15 Mcneil-Ppc, Inc. Simethicone/anhydrous calcium phosphate compositions
NZ333474A (en) * 1998-01-02 1999-06-29 Mcneil Ppc Inc A chewable tablet containing ibuprofen, fumaric acid and a non hydrocolloid binder e.g. a wax or a fat
US6274162B1 (en) * 2000-01-14 2001-08-14 Bpsi Holdings, Inc. Elegant film coating system
US7223421B2 (en) * 2000-06-30 2007-05-29 Mcneil-Ppc, Inc. Teste masked pharmaceutical particles
US6440983B1 (en) * 2000-12-21 2002-08-27 Mary Theresa Frank-Kollman Compositions and methods for relieving headache symptoms in aspirin-sensitive headache sufferers
AU2002244865A1 (en) * 2001-03-02 2002-09-19 Dr. Reddy's Laboratories Ltd. Pharmaceutical composition of ibuprofen
GB0113843D0 (en) * 2001-06-07 2001-08-01 Boots Co Plc Therapeutic agents
US7122143B2 (en) * 2001-09-28 2006-10-17 Mcneil-Ppc, Inc. Methods for manufacturing dosage forms
US6982094B2 (en) * 2001-09-28 2006-01-03 Mcneil-Ppc, Inc. Systems, methods and apparatuses for manufacturing dosage forms
US7323192B2 (en) * 2001-09-28 2008-01-29 Mcneil-Ppc, Inc. Immediate release tablet
KR20040045034A (ko) * 2001-09-28 2004-05-31 맥네일-피피씨, 인코포레이티드 변형된 방출형 제형
US7807197B2 (en) * 2002-09-28 2010-10-05 Mcneil-Ppc, Inc. Composite dosage forms having an inlaid portion
WO2007055887A1 (en) * 2005-11-02 2007-05-18 Teikoku Pharma Usa, Inc. Organoleptically acceptable ibuprofen oral dosage formulations, methods of making and using the same

Also Published As

Publication number Publication date
CA2667207A1 (en) 2008-05-02
US20080113021A1 (en) 2008-05-15
EP2094248A2 (en) 2009-09-02
BRPI0718428A2 (pt) 2013-11-12
AU2007308986A1 (en) 2008-05-02
WO2008052033A2 (en) 2008-05-02
WO2008052033A3 (en) 2008-06-12
CN101528205A (zh) 2009-09-09

Similar Documents

Publication Publication Date Title
MX2009004439A (es) Composicion de ibuprofeno.
MXPA05007643A (es) Metodo para producir una forma farmaceutica oral con desintegracion inmediata y liberacion de ingrediente activo.
UY29395A1 (es) Formulación de medicamentos conteniendo vardenafilo.
IL179718A0 (en) Pharmaceutical composition containing irbesartan
ECSP088560A (es) Formulacion de liberacion sostenida que comprende octreotida y dos o mas polimeros de polilactido-co-glicolido
PE20110010A1 (es) Formulaciones liquidas de fenilefrina
PE20001058A1 (es) Sistema de entrega controlado de droga administrado oralmente, que provee control temporal y espacial
DE602006014990D1 (de) Intranasale verabreichung von schnell wirkendem insulin
EP3895700A3 (en) Pharmaceutical compositions comprising iron oxy-hydroxide
MX2009003030A (es) Forma galenita para la administracion por via transmucosa de principios activos.
NO20080220L (no) Formuleringer med hoy medikament belastning og doseringsformer
CO6270217A2 (es) Formulaciones galenicas de alisquireno y valsartan
CY1109537T1 (el) Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης
EP1900368A4 (en) TABLET WITH A SPIRIT OF SOLUBLE ACTIVE SUBSTANCE
UY27929A1 (es) Composiciones farmaceuticas de farmacos semiordenados y polimeros
AR052044A1 (es) Composicion para el cuidado bucal y control del sarro que contiene extracto de magnolia
MX2010004556A (es) Formulacion farmaceutica de acido clavulanico.
AR062925A1 (es) Metodo para fabricar tabletas que contienen agentes farmacologicamente activos
EA200702496A1 (ru) Местная композиция, содержащая желатин
CL2004001843A1 (es) Combinacion de (a) al menos un derivado 2,5-dihidrobencenosulfonico, como el dobeilato calcico, etamsilato y persilato, y (b) al menos un modulador de los canales de potasio, composicion farmaceutica que la contiene y uso como medicamento en profilax
CL2007003451A1 (es) Composicion farmaceutica solida oral que comprende un principio activo y polivinilpirrolidona (pvp) entre 1,0-25%, cpaa entre 0,5-10%, el principio activo consiste en una sal hidrosoluble de metal alcalino, de metal alcalino-terreo, una sal de mezcla
UY29989A1 (es) Composiciones farmacéuticas de agentes hipnoticos de accion corta en forma de liberación modificada y los procedimientos para preparar dichas formulaciones
UY29403A1 (es) Composiciones farmacéutica sólida que comprende telitromicina.
GT200600353A (es) Forma farmaceutica con liberacion sostenida independiente del ph de un ingrediente activo, para ingredientes activos que tienen una solubilidad que depende en gran medida del ph.
ATE357220T1 (de) Pharmazeutische zusammensetzung mit modifizierter freisetzung

Legal Events

Date Code Title Description
FA Abandonment or withdrawal